703
Views
9
CrossRef citations to date
0
Altmetric
Research Article

The effects of qindan-capsule-containing serum on the TGF-β1/ERK signaling pathway, matrix metalloproteinase synthesis and cell function in adventitial fibroblasts

, , , , , , & show all
Pages 712-721 | Received 16 Sep 2012, Accepted 03 Jan 2013, Published online: 04 Feb 2013

Figures & data

Table 1. Recipe for qindan-capsule formulation.

Table 2. Quality evaluation of the qindan-capsule compound.

Table 3. Primers for RT-PCR.

Figure 1. Identification of AFs: (A) AFs cells (100×); (B) negative expression of SMA by immunocytochemistry (100×); and (C) positive expression of vimentin by immunocytochemistry (100×).

Figure 1. Identification of AFs: (A) AFs cells (100×); (B) negative expression of SMA by immunocytochemistry (100×); and (C) positive expression of vimentin by immunocytochemistry (100×).

Figure 2. The effects of drug-containing serum on AF migration. AFs were treated with TGF-β1 for 24 h. Cell migration was measured with the transwell assay. The values shown represent the mean ± SEM, n = 3. &, p < 0.01 compared to NC; #, p < 0.05 compared to PC; *, p > 0.05 compared to losartan; Student’s t-test.

Figure 2. The effects of drug-containing serum on AF migration. AFs were treated with TGF-β1 for 24 h. Cell migration was measured with the transwell assay. The values shown represent the mean ± SEM, n = 3. &, p < 0.01 compared to NC; #, p < 0.05 compared to PC; *, p > 0.05 compared to losartan; Student’s t-test.

Figure 3. The effects of drug-containing serum on AF proliferation. AFs were treated with TGF-β1 for 24 h. Cell growth was measured with the MTT assay. The values shown represent the mean ± SEM, n = 3. &, p < 0.01 compared to NC; #, p < 0.05 compared to PC; ##, p < 0.01 compared to PC; *, p > 0.05 compared to losartan; **, p < 0.05 compared to losartan; Student’s t-test.

Figure 3. The effects of drug-containing serum on AF proliferation. AFs were treated with TGF-β1 for 24 h. Cell growth was measured with the MTT assay. The values shown represent the mean ± SEM, n = 3. &, p < 0.01 compared to NC; #, p < 0.05 compared to PC; ##, p < 0.01 compared to PC; *, p > 0.05 compared to losartan; **, p < 0.05 compared to losartan; Student’s t-test.

Figure 4. The effects of drug-containing serum on the AF cell cycle. AFs were treated with TGF-β1 for 24 h. Cell cycle progression was evaluated by flow cytometry. The values shown represent the mean ± SEM, n = 3. &, p < 0.01 compared to NC; $, p < 0.05 compared to NC; &&, p > 0.05 compared to NC; ##, p < 0.05 compared to PC; #, p > 0.05 compared to PC; *, p > 0.05 compared to losartan; Student’s t-test.

Figure 4. The effects of drug-containing serum on the AF cell cycle. AFs were treated with TGF-β1 for 24 h. Cell cycle progression was evaluated by flow cytometry. The values shown represent the mean ± SEM, n = 3. &, p < 0.01 compared to NC; $, p < 0.05 compared to NC; &&, p > 0.05 compared to NC; ##, p < 0.05 compared to PC; #, p > 0.05 compared to PC; *, p > 0.05 compared to losartan; Student’s t-test.

Figure 5. The effects of drug-containing serum on AF apoptosis. AFs were treated with TGF-β1 for 24 h. Cell apoptosis was measured by flow cytometry. (A) Representative data shows apoptosis cells. (B) Columns, mean of data obtained from three independent experiments. Bar mean SEM. &, p < 0.01 compared to NC; ##, p < 0.05 compared to PC; #, p < 0.01 compared to PC; *, p > 0.05 compared to losartan; Student’s t-test.

Figure 5. The effects of drug-containing serum on AF apoptosis. AFs were treated with TGF-β1 for 24 h. Cell apoptosis was measured by flow cytometry. (A) Representative data shows apoptosis cells. (B) Columns, mean of data obtained from three independent experiments. Bar mean SEM. &, p < 0.01 compared to NC; ##, p < 0.05 compared to PC; #, p < 0.01 compared to PC; *, p > 0.05 compared to losartan; Student’s t-test.

Figure 6. ERK1/2, CTGF, MMP2 and MMP9 expression. (A) and (B): protein levels of ERK1/2, p-ERK1/2, CTGF, MMP2 and MMP9. The values shown represent the mean ± SEM, n = 3. &&, p < 0.05 compared to NC; $, p < 0.01 compared to NC; &, p > 0.05 compared to NC; #, p > 0.05 compared to PC; ##, p < 0.05 compared to PC; @, p < 0.01 compared to PC; *, p > 0.05 compared to losartan; **, p < 0.05 compared to losartan; %, p < 0.01 compared to losartan; Student’s t-test. (C) and (D): CTGF, MMP2 and MMP9 mRNA expression. The values shown represent the mean ± SEM, n = 3. $, p < 0.05 compared to NC; $, p < 0.01 compared to NC; &&, p > 0.05 compared to NC; ##, p < 0.05 compared to PC; #, p > 0.05 compared to PC; *, p > 0.05 compared to losartan; **, p < 0.05 compared to losartan; Student’s t-test.

Figure 6. ERK1/2, CTGF, MMP2 and MMP9 expression. (A) and (B): protein levels of ERK1/2, p-ERK1/2, CTGF, MMP2 and MMP9. The values shown represent the mean ± SEM, n = 3. &&, p < 0.05 compared to NC; $, p < 0.01 compared to NC; &, p > 0.05 compared to NC; #, p > 0.05 compared to PC; ##, p < 0.05 compared to PC; @, p < 0.01 compared to PC; *, p > 0.05 compared to losartan; **, p < 0.05 compared to losartan; %, p < 0.01 compared to losartan; Student’s t-test. (C) and (D): CTGF, MMP2 and MMP9 mRNA expression. The values shown represent the mean ± SEM, n = 3. $, p < 0.05 compared to NC; $, p < 0.01 compared to NC; &&, p > 0.05 compared to NC; ##, p < 0.05 compared to PC; #, p > 0.05 compared to PC; *, p > 0.05 compared to losartan; **, p < 0.05 compared to losartan; Student’s t-test.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.